^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    praluzatamab ravtansine (CX-2009)

    i
    Company:
    AbbVie, CytomX
    Drug class:
    Microtubule inhibitor, CD166-targeted antibody-drug conjugate
    Related drugs:
    Apply
    Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer (CTMX-2009-002) (NCT04596150)
    Phase 2
    CytomX Therapeutics
    Completed
    Last update posted :
    01/23/2024
    Initiation :
    12/29/2020
    Primary completion :
    06/02/2023
    Completion :
    06/02/2023
    HER-2 • PD-L1
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive
    |
    praluzatamab ravtansine (CX-2009) • pacmilimab (CX-072)